fda warning letters compounded tirzepatide 2024 2025 π¨ Moves to Permanently Shut Down GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like semaglutide and tirzepatide, signaling a major shift in how these From Crackdown to Collaboration: FDA
Description
It is important to note that semaglutide products are not indicated for type 1 diabetes
This suggests that NAD+ repletion can have metabolic benefits in humans, though the magnitude depends on baseline NAD+ status and the specific precursor used
Researchers in 2026 should evaluate both compounds against current Phase 3 data as it becomes available
It lets you cheer for what you achieve
The company has secured a regulatory priority voucher that can accelerate review time, potentially giving the pill an edge as more oral competitors move through the pipeline
